| Pharmaceutical Information |
| Drug Name |
Agalsidase beta |
| Drug ID |
BADD_D00049 |
| Description |
Agalsidase beta is a recombinant human α-galactosidase A similar to [agalsidase alfa]. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009.[A220343]
Agalsidase beta was granted FDA approval on 24 April 2003.[L16383] |
| Indications and Usage |
Agalsidase beta is indicated in the treatment of Fabry disease.[L16383] |
| Marketing Status |
approved; investigational |
| ATC Code |
A16AB04 |
| DrugBank ID |
DB00103
|
| KEGG ID |
D03228
|
| MeSH ID |
C459420
|
| PubChem ID |
52918379
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
58468-0040; 58468-0041 |
| UNII |
RZD65TSM9U
|
| Synonyms |
agalsidase beta | Fabrazyme |
|
| Chemical Information |
| Molecular Formula |
C50H78N4O14 |
| CAS Registry Number |
928659-70-5 |
| SMILES |
CCCCCCCC(=O)NC(CN1CCCC1)C(C2=CC3=C(C=C2)OCCO3)O.CCCCCCCC(=O)NC(CN1CCCC1)C(C2=CC3
=C(C=C2)OCCO3)O.C(C(C(=O)O)O)(C(=O)O)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
